Gene therapy for liver disease advancing with the help of adeno-associated viral vectors

December 30, 2016
Credit: Mary Ann Liebert, Inc., publishers

Liver-directed gene therapy delivered using adeno-associated viral (AAV) vectors to treat diseases such as hemophilia have advanced into human testing. The potential for continued technological improvements to expand the therapeutic applications of gene therapy to treat liver disorders and the remaining clinical challenges are examined in a comprehensive review article published in Human Gene Therapy.

In the article "Adeno-Associated Virus Gene Therapy for Liver Disease," Lisa Kattenhorn and coauthors from Dimension Therapeutics, Cambridge, MA, provide historical context for the remarkable progress achieved using this viral particular delivery vector to target therapeutic genes to the . The authors describe the preclinical and clinical studies that have led to a better understanding of immune responses to AAV gene therapy. In addition, they explore areas for future development and current challenges, including readministration of AAV and minimizing the risk of hepatocellular carcinoma.

"AAV-based genet therapy to the liver has been a platform for transformational new therapies for genetic diseases such as hemophilia and inborn errors of metabolism," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "The review by Dr. Kattenhorn and colleagues provides an excellent overview of the current best knowledge in this area."

Explore further: Gene therapy to prevent vision loss: Studies in primates needed to optimize human trials

More information: Lisa M. Kattenhorn et al, Adeno-Associated Virus Gene Therapy for Liver Disease, Human Gene Therapy (2016). DOI: 10.1089/hum.2016.160

Related Stories

New gene therapy strategies emerging to combat vision loss

June 22, 2016

Diseases of the eye that cause vision loss and blindness, especially neurodegenerative disorders affecting the retina, are ideal targets for gene therapy, including gene replacement and promising corrective gene editing strategies. ...

Recommended for you

Epigenetic factors linked to obesity-related disease

January 17, 2017

Obesity has been linked to "letter" changes at many different sites in the genome, yet these differences do not fully explain the variation in people's body mass index (BMI) or why some overweight people develop health complications ...

Are you ready to explore baby's genome?

January 17, 2017

When you have a baby, a nurse or a phlebotomist performs a heel stick to take a few drops of blood from your infant and sends it off to a state lab for a battery of tests. Most of the time, you never hear about the results ...

Study applies game theory to genomic privacy

January 17, 2017

It comes down to privacy—biomedical research can't proceed without human genomic data sharing, and genomic data sharing can't proceed without some reasonable level of assurance that de-identified data from patients and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.